Amatuximab (MORAb-009)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 02:36, 2 December 2016 by Dryang (talk | contribs) (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm")
Jump to navigation Jump to search

Mechanism of action

Anti-mesothelin monoclonal antibody

Preliminary data

Mesothelioma

  1. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Amatuximab_(MORAb-009)&oldid=12543"